Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type

Annals of Hematology

Volumn 93, Issue 2, 2014, Pages 333-334

  Savini, P ^a   Lanzi, A ^a   Foschi, F G ^a   Marano, G ^a   Stefanini, G F ^a  

^a Ospedale di Faenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; LENALIDOMIDE; THALIDOMIDE;

ANALOGS AND DERIVATIVES; CASE REPORT; FEMALE; HUMAN; LEG; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY; SKIN NEOPLASMS; VERY ELDERLY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; LEG; LYMPHOMA, LARGE B-CELL, DIFFUSE; SKIN NEOPLASMS; THALIDOMIDE;

EID: 84895060608     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1787-0     Document Type: Letter

References (6)

1. Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785
2. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M et al (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19:3602-3610
3. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600-1609
4. Senff NJ, Hoefnagel JJ, Neelis KJ et al (2007) Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 143:1520-1526
5. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4(4):314-322
6. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22(7):1622-1627